Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
10.70
+0.04 (0.42%)
Aug 8, 2025, 10:47 AM - Market open
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Verve Therapeutics stock has a target of 10.3, which predicts a -3.69% decrease from the current stock price of 10.7.
Price Target: $10.3 (-3.69%)
Analyst Consensus: Hold
* Price targets were last updated on Jun 17, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Verve Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $7.6 → $10 | Hold | Maintains | $7.6 → $10 | -3.69% | Jun 17, 2025 |
| Deutsche Bank | Deutsche Bank | Hold → Strong Sell Downgrades n/a | Hold → Strong Sell | Downgrades | n/a | n/a | Mar 12, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $10 → $11 | Hold | Maintains | $10 → $11 | -1.82% | Dec 5, 2023 |
| Deutsche Bank | Deutsche Bank | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 5, 2021 |
| Credit Suisse | Credit Suisse | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Mar 23, 2021 |
Financial Forecast
Revenue This Year
7.60B
from 7.21B
Increased by 5.40%
Revenue Next Year
8.11B
from 7.60B
Increased by 6.74%
EPS This Year
0.78
from 0.23
Increased by 239.96%
EPS Next Year
1.03
from 0.78
Increased by 32.08%
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.0B | 8.6B | 9.3B | ||
| Avg | 7.6B | 8.1B | 8.7B | ||
| Low | 7.2B | 7.7B | 8.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.4% | 13.3% | 14.4% | ||
| Avg | 5.4% | 6.7% | 7.3% | ||
| Low | 0.5% | 0.7% | -0.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.09 | 1.39 | 1.66 | ||
| Avg | 0.78 | 1.03 | 1.22 | ||
| Low | 0.55 | 0.72 | 0.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 374.8% | 77.3% | 60.6% | ||
| Avg | 240.0% | 32.1% | 18.3% | ||
| Low | 138.6% | -8.5% | -8.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.